Founded with a mission to empower informed parenting, Fortuna Genomics leverages cutting-edge genomic technologies to provide non-invasive genetic screening and forecasting for embryos. Their core vision is to optimize children's innate qualities, such as intelligence and health, without the need for gene editing. By offering comprehensive genetic assessments, Fortuna Genomics aims to help families make well-informed decisions about their child's potential from conception.

Notable figures and investors in the field of genomics have shown interest in Fortuna Genomics, recognizing its innovative approach to genetic screening. The company has achieved significant milestones in sequencing efficiency and association studies, positioning itself as a leader in the non-invasive genetic screening market. Its impact lies in providing a scientifically grounded method for parents to enhance their children's well-being and capabilities, potentially revolutionizing the approach to human development.